Evidence map›Paper›PMID 39020448›Full record

ArticleStem cell research & therapy2024

Mesenchymal stem cells-derived extracellular vesicles ameliorate lupus nephritis by regulating T and B cell responses.

Cuifang Li, Feifeng Wu, Jueyi Mao, Yang Wang, Junquan Zhu, Kimsor Hong, Haotian Xie, Xin Zhou, Jidong Tian, Chuan Wen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. CD126Orphanet journal of rare diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cuifang Li *Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Feifeng Wu *Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Jueyi Mao *Department of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Yang WangDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Junquan ZhuDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Kimsor HongDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Haotian XieDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Xin ZhouDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Jidong TianDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, 410011, China.
Chuan WenDepartment of Pediatrics, The Second Xiangya Hospital of Central South University, Changsha, 410011, China. chuanwen@csu.edu.cn.ORCID 0000-0001-6955-670X

Funding

Health Commission of Hunan Province No. 202206012608National Natural Science Foundation of China No. 82070758
6 · The paper itself

Abstract

backgroundHuman umbilical cord mesenchymal stem cells-derived extracellular vesicles (hUCMSC-EVs) have potent immunomodulatory properties similar to parent cells. This study investigated the therapeutic effects and immunomodulatory mechanisms of hUCMSC-EVs in an experimental lupus nephritis model.

methodsThe hUCMSC-EVs were isolated by using differential ultracentrifugation. In vivo, the therapeutic effects of hUCMSC-EVs in lupus-prone MRL/lpr mice were investigated, and the mechanisms of treatment were explored according to the abnormal T and B cell responses among both the spleen and kidney.

resultsMRL/lpr mice treated with hUCMSC-EVs reduced proteinuria extent, serum creatinine and renal pathological damage; decreased splenic index and serum anti-dsDNA IgG level; and improved survival rate. hUCMSC-EVs lowered the percentage of T helper (Th)1 cells, double-negative T (DNT) cells, and plasma cells among splenocytes; inhibited the infiltration of Th17 cells but promoted regulatory T (Treg) cells in the kidney, followed by a reduction in pro-inflammatory cytokine levels(IFN-γ, IL-2, IL-6, IL-21, and IL-17 A). In addition, hUCMSC-EVs inhibited the activation of STAT3 and down-regulated IL-17 A protein levels in the kidney.

conclusionThe results of this study demonstrated that hUCMSC-EVs had therapeutic effects on experimental lupus nephritis (LN) by regulating Th1/Th17/Treg imbalance and inhibiting DNT and plasma cells. Additionally, hUCMSC-EVs inhibited Th17 cell differentiation in kidney by regulating the IL-6/STAT3/IL-17 signal pathway, which might be an important mechanism for alleviating renal injury. Taken together, we demonstrated that hUCMSC-EVs regulating T and B cell immune responses might represent a novel mechanism of hUCMSCs in treating LN, thus providing a new strategy for treating LN.

Indexed as

Extracellular VesiclesLupus NephritisMesenchymal Stem CellsMice, Inbred MRL lprAnimalsB-LymphocytesCytokinesDisease Models, AnimalFemaleHumansKidneyMiceSpleenSTAT3 Transcription FactorTh17 CellsT-Lymphocytes, RegulatoryCytokinesSTAT3 Transcription FactorB cellExtracellular vesiclesLupus nephritisMesenchymal stem cellsT cell

Identifiers

PMID39020448
PMCPMC11256400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.